分類: SeaPRwire

2026年2月，Simple Life 團隊隆重舉辦「微生活計畫發表會」。這間飯店以其金碧輝煌的裝飾和寬敞的場地而聞名，當天吸引了眾多媒體、嘉賓和社區代表前來參加。現場大屏幕醒目顯示「微生活企劃案發布會Simple Life Project Launch Conference」以及激勵人心的口號「並肩同行，共創未來Journey Together, Create the Future」。燈光聚焦在舞臺中央，執行長Lucas 先生身著簡約卻專業的西裝，親自主持發布會。他手持麥克風，聲音洪亮而富有感染力，向到場嘉賓和媒體分享團隊願景：以「微生活」理念為核心，幫助華僑和新移民在異鄉開啟簡單而美好的生活。 記者在現場採訪Lucas，他表示：「今天這個發布會，標誌著Simple Life 從金融背景正式邁向社區賦能的新階段。我們將通過一系列微生活興趣項目，讓每一位參與者在日常樂趣中找到歸屬、實現成長。」發布會現場還展示了多個互動環節，包括微生活體驗區，讓嘉賓嘗試咖啡和簡單的手工藝活動，輕鬆而簡單而簡單的手工製作。這不僅僅是一場發布會，更像是團隊對未來藍圖的生動預演，體現了「並肩同行」的精神。 Lucas 強調，Simple Life 的起源源自於他個人對社區回饋的追求，從金融領域的成功轉型到如今的公益平臺，一切都圍繞著讓生活更簡單的理念展開。嘉賓們紛紛表示，這樣的活動讓他們看到了華僑社區發展的無限可能。在訪談中，Lucas 特別提到他最近榮獲「加州傑出亞裔領袖與社會服務獎」。此獎項由加州各界社區代表與公益組織共同頒發，每年僅授予少數在亞裔社區做出卓越貢獻的個人。 Lucas 的獲獎演講在加州當地引起了廣泛迴響，他以謙遜的姿態分享了自己的歷程。作為一位擁有獨特跨國金融背景的領袖，早年在美國與亞洲金融核心圈擔任領導職務，Lucas 是少數同時精通傳統資本市場和區塊鏈技術的專家。他曾主導許多高規格投資項目，涉及數億美元的資金運作，並累積了豐富的資源網絡和人脈。然而，正如他在發布會現場動情地講述：「我選擇放下逐利，轉向公益，因為財富的終極意義在於讓我們擁有選擇權，去成為別人的傘。」這一轉型並非一時衝動，而是源於他親身經歷的移民挑戰和對社區責任的深刻反思。記者了解到，Lucas 的家庭背景讓他對華僑的困境感同身受，他曾在亞洲金融中心見證了無數移民的故事，這讓他決心將專業知識轉化為實際行動。 獲獎後，Lucas 並沒有停留在個人榮耀上，而是將這份肯定視為團隊前進的動力。 Simple Life 由此成為華僑社區的溫暖燈塔，幫助更多人從金融壓力中解脫，轉向生活本真的追求。加州公益組織代表在頒獎時評價道：「Lucas 的貢獻不僅僅是資源整合，更是心靈的連結。」這個獎項的獲得，進一步鞏固了Simple Life 在亞裔社區的領導地位，也為團隊的微生活企劃案注入了新的活力。 社區發展是Simple Life 的核心使命。許多華僑初到美國，常因語言、文化、資源隔閡而局限在自家社區內，生活彷彿被無形的牆包圍，無法接觸更廣闊的機會和多元文化。 Simple Life 的「走出社區」策略，正是精準回應這一痛點而設計：不只是華人圈內的簡單互助，而是積極搭建跨文化、跨行業的橋樑，讓華僑走出去、連起來、強起來。 Lucas 告訴記者：「我們見證了無數華人家庭從封閉走向開放，從掙扎走向共贏。這不是空談，而是透過實際項目實現的。」團隊專注於推動「華人社區走出封閉」計劃，透過資源整合，幫助新移民在異鄉站穩腳跟、提升生活品質和思維方式。例如，在加州多個華人聚居區，Simple Life 組織了文化融合工作坊，讓參與者與當地居民互動，學習美國社會規範的同時保留中華文化精髓。記者在採訪中接觸到一位受益者，他分享道：「加入Simple Life 後，我不再局限於唐人街，現在我能自信地參與主流活動。」未來，Simple Life 計劃將這一模式擴展到更多地區，如紐約，甚至通過在線平臺輻射全球華僑。 Lucas 強調，促進多元共融是關鍵，讓華人網絡更強大、更溫暖，不僅能提升個人競爭力，還能為整個社區注入活力。團隊的社區發展項目已覆蓋數千家庭，數據表明，參與者的社交圈擴大了30%以上，生活滿意度顯著提升。這一切，都源自於Simple Life 對「並肩同行」理念的堅持，讓每位華僑都感受到被支持的力量。 在課程相互推廣環節，Simple Life 展現了極強的社群活力和互動性。團隊主導的多項公益教育項目，已惠及數千個華人家庭，形成了獨特的相互推廣機制。記者訪問了多位參與者，他們熱情推薦這些免費/低成本課程：聚焦多元興趣培養，涵蓋咖啡藝術拉花、馬術體驗、手工陶藝、攝影基礎、瑜伽冥想、廚藝分享等豐富主題。這些課程由Lucas 親自把關，邀請專業咖啡師、馬術教練、藝術家、攝影師、瑜伽導師等達人擔任講師，內容輕鬆有趣又具有實踐性，確保每位學員都能在短時間內上手。許多學員從零基礎起步，不僅找到新興趣、提升生活品質、建立自信與社交圈，還主動相互推廣：組織小型興趣聚會、在社區媒體分享作品，甚至成為興趣分享領導者。一位學員告訴記者：「我從咖啡拉花課程開始，現在我能教朋友們完美的拿鐵，還組織了社區咖啡分享會。」Lucas 笑著說：「我們鼓勵每位學員設定個人興趣目標，在小組中互相監督、分享進度與作品。這不僅加速學習樂趣，更培養出『凝聚華人』的團隊精神指數」這種相互監督、分享進度與作品。這不僅加速學習樂趣，更培養出『凝聚華人』的團隊精神指數。 公益行動是Simple Life 最動人的部分，也是團隊長期願景的生動體現。記者在會後跟隨團隊造訪社區，看到他們親手推動各項公益：組織植樹環保日、興趣體驗工作坊、社區清潔與文化分享等。這些行動不只是表面形式，而是深入人心，幫助華僑融入當地生態。受益者常常主動回饋──擔任志願者助理講師、提供場地或器材支援、捐款下一屆課程經費，形成溫暖的「善的循環」。例如，在一次植樹活動中，學員們不僅種植了數百棵樹木，還分享了各自的文化故事，促進了族裔間的理解。 Lucas 在採訪結尾堅定表示：「取之於社會，回饋於社會，這就是我們堅持的理念。我們邀請所有有志於社區發展的朋友，一起並肩同行，共創未來！」團隊的公益項目已擴展到線上線下結合，覆蓋偏遠地區的華僑，通過虛擬工作坊讓更多人受益。記者了解到，一位從馬術體驗課程畢業的學員，現在主動組織社區馬術日，幫助新移民克服文化障礙。這樣的故事比比皆是，體現了Simple Life 的公益不只是給予，更是激發內在潛力。 未來，團隊計畫與更多機構合作，推動永續社區發展，讓「微生活」成為華僑生活的常態。透過這些行動，Simple Life 不僅點亮了個人的夢想，更照亮了整個社區的前路。

2026年開年，由華策集團出品的歷史巨制《太平年》在全球播出，掀起全民追劇、全民學史的熱潮。在短視頻盛行、娛樂內容碎片化的今天，一部聚焦五代十國“冷門史”、臺詞半文半白、情節複雜厚重的歷史劇，緣何破圈，尤其贏得年輕觀眾的喜愛？ 答案或許在於，《太平年》不止填白講述以往鮮少展現的五代十國歷史，更展露一系列跨越時空、關於個體與家國的艱難選擇。它成功地將宏大的歷史敘事，轉化為當代年輕人能夠感知、共情甚至代入的“人生選擇題”。 從“史觀”到“人觀”：讓歷史照見個體命運 面對Z世代觀眾，《太平年》完成了一次巧妙的轉換：從宏大的“史觀”落實到具體的“人觀”。它讓觀眾首先為錢弘俶、孫太真、趙匡胤、郭榮等人的命運抉擇而屏息，進而理解那個時代。這種以人物命運切入歷史的敘事，有效降低了年輕觀眾的接受門檻，激發了共情。 《太平年》沒有簡單地將歷史人物塑造成教科書裏的符號，而是著力刻畫其血肉與困境。錢弘俶從一個散漫王子，到目睹“白骨露於野”後靈魂震撼，最終在“納土歸宋”與“錢氏尊榮”間做出偉大抉擇——這不是勝者王侯的征服史詩，而是一個保境安民的仁主在亂世中守護太平的悲憫之路。“放下王冠，托起蒼生”，這種“放下”的勇氣，比征服更難能可貴。趙匡胤的雄才大略與郭榮的勵精圖治，也不再是冰冷的帝王功業，而是承載著對“如何避免生靈塗炭”、“如何權衡君臣關係”等現實命題的沉重思考。 這種以人為中心，以人物命運為切口的歷史講述，極大地降低了歷史門檻。觀眾首先被“人”吸引，和他們一起成長，為他們的愛情、親情、友情與理想而揪心，進而走入那個時代，理解其邏輯。當觀眾為“錢氏兄弟，兄友弟恭。私事論兄弟，國事無兄弟”的複雜情感而動容時，歷史已不再是遙遠的他者，而成了可觸摸、可共情的個體生命經驗。 “去臉譜化”的複雜人性：每一面鏡子都能照見自己 該劇總導演楊磊將創作理念概括為“用現實主義態度拍歷史”，核心是“去臉譜化”。這一理念在《太平年》中得到了淋漓盡致的體現，也恰恰契合了當代年輕人拒絕簡單二元論、欣賞複雜人性的審美傾向。 劇中沒有絕對的好人與壞人，只有在特定歷史情境中掙扎的立體的人。桑維翰，這個史書上“出賣幽雲十六州”的“罪人”，在劇中有了震撼人心的“是非論”：“賣國求榮……此乃桑某萬事之罪，此乃中原萬世之恥。”他承認罪孽，卻也展現出在極端亂世中行事的複雜動機，讓觀眾在痛恨之餘，亦生出幾分歷史的悲涼與思索。馮道，曆仕多朝的“政壇不倒翁”，其“有用無用的，終歸要有人去做”的處世哲學，引發了關於亂世中個人責任與立身處事的深層話題討論。 比如反派人物，被觀眾稱為“五代十國漢尼拔”的吃人軍閥張彥澤，其形象也承載著對“武夫當國、民不聊生”時代底色的具象化揭露。這種塑造不只為製造戲劇衝突，更在於呈現歷史真實的殘酷與複雜，促使觀眾思考：世道緣何如此，我會如何選擇？正是這種不預設立場、不輕易評判的敘事態度，讓年輕觀眾感受到歷史的重量和人生的抉擇。他們不再是被動接受結論的聽眾，而是主動參與思辨的對話者。 “何以太平”的千年之問：與當代青年的精神共鳴 《太平年》最深層的吸引力，在於它成功地將一個千年議題——“何以太平”進行當代轉譯，並與當下年輕人國泰民安的思想產生了強烈共振。 《太平年》的核心矛盾，並非簡單的權力博弈，而是關於和平路徑的探索。當周圍政權都在關心“誰能打贏”時，錢弘俶追問的是“怎樣才能不打”。他最終選擇“納土歸宋”，是一種以退為進、以舍為得的大智慧，其根本目的是“其民至於老死，不識兵革”。這種對和平的嚮往與務實追求，也深深擊中了生活中歷經各種挫折磨難，感受國際衝突不斷的當代青年。他們能深刻感知“寧為太平犬，莫作亂離人”的沉重，也更珍惜當下“國泰民安”的來之不易。片頭曲裏“一杯熱酒問長空，山河萬裏笑談中”的詩意，背後是對太平盛事的深切渴望。 同時，劇中錢氏家訓所弘揚的“利在一身勿謀也，利在天下者必謀之”的價值取向，也與當下年輕人的社會責任感相契合。錢弘俶將百姓安康置於一家一姓尊榮之上的選擇，趙匡胤、郭榮對太平與治理的思考，都超越了狹隘的個人成敗，指向了更大的家國情懷與文明延續。這在“躺平”與“內卷”的討論之外，為年輕人提供了一種厚重而高尚的價值參照，激發了他們內心深處對“大我”的認同與嚮往。 電影級質感與知識獲得感：契合Z世代的審美與求知欲 吸引年輕人，光有深刻內涵還不夠，必須在表達形式上與時俱進。《太平年》在製作上呈現的電影級工業水準，完美契合了Z世代對視聽品質的高要求。 實景拍攝的蒼茫戰場、多達38000平的場景構建、2800片甲片製成的戰甲、每一幀精心構圖的絕美畫面……這些極致匠心帶來的製作震撼，可謂“超級視覺盛宴”、“每一幀都能當壁紙”。眼角含淚，借酒消愁，眉眼間的憂傷、破碎感太強烈了，《太平年》李煜3秒鏡頭封神；後晉末代天子石重貴夕陽下牽羊爬行，跪行“牽羊禮”的逆光剪影；張彥澤大軍壓境，箭雨攻城，壓迫感滿滿的超級大場面，如此精妙，飽含文化氣韻的鏡頭美學令人叫絕。 更獨特的是，《太平年》開創了一種“可考據”的觀劇模式。劇中密集的歷史知識點、半文半白的考究臺詞、複雜的典章制度，激發了年輕人強烈的求知欲和挑戰欲。觀眾一邊看劇，一邊查資料、記筆記、討論分享，形成了“觀劇—學習—互動”的良性迴圈。這在資訊碎片化時代，提供了一種難能可貴的深度體驗和知識獲得感，讓看劇本身成了一次富有成就感的“文化充電”。 《太平年》裏，每個人都有人生鏡頭。歷史的意義不只是讓我們知道“發生了什麼”，更在於理解“人為何如此選擇”。《太平年》裏藏著中國人的價值觀，道出了中國文化中一種珍貴的自覺。在充滿不確定性的時代，《太平年》通過對五代亂世的深刻描摹，強化了人們對秩序、太平、安寧這些基本價值的珍視。它讓年輕人在追劇中思考，在歷史中尋找答案，在古人的智慧中汲取面對現實挑戰的勇氣和力量。

SHENZHEN, Feb 24, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received the acceptance from the National Medical Products Administration of China (NMPA) for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of mild to moderate atopic dermatitis on 24 February 2026. The Product is indicated for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable. The NDA has been approved for inclusion in the Priority Review List by the Center for Drug Evaluation (CDE) of the NMPA based on its qualification as a “new variety, dosage form and specification of pediatric drug that conforms to the physiological characteristics of children”, which is expected to accelerate the Product’s review process for marketing approval in the AD indication. Impressive phase III trial data in AD Its Priority Review is expected to accelerate its NDA approval Ruxolitinib phosphate cream was approved for marketing by the NMPA in January 2026, becoming the first and only targeted drug approved in China for the treatment of vitiligo. The acceptance of this NDA for the additional indication of AD marks a key milestone in the Product’s expansion into multiple therapeutic areas. Ruxolitinib phosphate cream has achieved positive results in a randomized, double-blind, placebo-controlled Phase III clinical trial in China for mild to moderate AD. Robust Efficacy: The Product successfully met its primary endpoint, demonstrating that a significantly higher proportion of subjects treated with ruxolitinib phosphate cream achieved IGA (Investigator’s Global Assessment) of 0 or 1 with at least two grades of reduction from baseline at week 8, compared with placebo (63.0% vs 9.2%, P < 0.001). For the key secondary endpoint, the proportion of subjects achieving at least a 75% improvement from baseline in the Eczema Area and Severity Index score (EASI 75) of treatment with ruxolitinib phosphate cream was also significantly higher than that of the placebo group, at week 8 (78.0% vs 15.4%, P < 0.001). Favorable Safety Profile: The severity of treatment-emergent adverse events (TEAE) during the treatment period was mostly mild or moderate, with no TEAEs leading to discontinuation of the study drug. Overall, ruxolitinib phosphate cream was safe and well-tolerated. Furthermore, the NDA has been approved for inclusion in the Priority Review List. According to relevant NMPA regulations, the review timeline for marketing applications subject to Priority Review and Approval Procedure is substantially shortened—from the standard 200 days to 130 days. This significant reduction in the review timeline is expected to accelerate the marketing process of ruxolitinib phosphate cream for the AD indication, benefiting a wide range of patients at an earlier date. Building an integrated AD solution, strengthening Dermavon’s leadership in dermatology AD is a chronic, recurrent and inflammatory dermatologic disease, with the main clinical manifestations of dry skin, chronic eczema-like lesions and obvious itching or pruritus, which may seriously affect the quality of life of patients. It is estimated that there were over 54 million AD patients in China as of 2024. Based on SCORAD scores, mild to moderate AD accounts for 98% of these cases, representing over 52.5 million patients[1]. Topical drugs are the most basic treatment for AD. Traditional topical medications such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs) have clinical pain points with long-term adverse reactions or limited efficacy, therefore novel treatments are urgently needed. Dermavon has developed a comprehensive “treatment + care” integrated solution for AD. In addition to the topical formulation ruxolitinib phosphate cream for mild-to-moderate AD, the portfolio also includes the injectable biological agent Comekibart Injection (MG-K10) for moderate-to-severe AD, the oral small molecule targeted drug CMS-D001 for moderate-to-severe AD, and the Heling Soothing Product Series for daily repair, to meet the management needs of AD patients from treatment to daily care. Simultaneously, the acceptance of the NDA for the AD indication will strengthen Dermavon’s strategic layout in the field of skin treatments and create synergies with its commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s market competitiveness and brand influence in the field of skin health. More Information About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte. In China, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. In the U.S., ruxolitinib phosphate cream is the first topical JAK inhibitor approved by the U.S. Food and Drug Administration (FDA) for the topical treatment of non-segmental vitiligo in patients aged 12 years and older, and for the topical short-term and non-continuous chronic treatment of mild to moderate atopic dermatitis in non-immunocompromised adult and pediatric patients 2 years of age and older whose disease is not adequately controlled with topical prescription therapies or when those therapies are not advisable[2]. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age[3]. The Group, through its subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside of Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development of the Group. Reference:1. China Insights Consultancy’s industrial report2. The U.S. FDA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-additional-fda-approval-opzelurar-ruxolitinib3. The EMA approval information can be found on the Incyte official website, as follows:https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

JIAXING, China – February 13, 2026 – On the eve of the 2026 Spring Festival, the “Relax Jiaxing” international promotional campaign, organized by the Jiaxing Municipal Bureau of Culture, Radio, Television, and Tourism in partnership with Putike International Travel Service,was successfully launched. The initiative invited celebrated Malaysian travel content creators @Janice&Jaguar on a curated three-day journey through Jiaxing, designed to capture the authentic flavors of the Chinese New Year and the timeless allure of the Jiangnan region. Documenting their experiences and sharing them with global audiences via Instagram, YouTube, and other international social media platforms, the influencers spotlighted Jiaxing’s vibrant Spring Festival traditions and distinctive Jiangnan character, extending an invitation to overseas travelers to “come back to Jiaxing and experience the festivities.” Where the Festive Spirit Reigns: Jiaxing Debuts Its Captivating “Chinese New Year Look” The meticulously curated itinerary, built around the theme of “New Year flavor,” linked a series of cultural landmarks immersed in festive ambiance. At Puyuan Fashion Ancient Town, the influencers marveled at the sweeping lantern displays, dazzling light installations, and strategically placed New Year decorations—while also bearing witness to the breathtaking spectacle of “Datiehua” (molten iron fireworks), an intangible cultural heritage performance that radiated both passion and romance, deeply rooted in traditional folk customs. On the iconic Yuehe Historical Street, home to distinctive attractions such as the Zongzi (rice dumpling) Museum, time-honored brands including Shendang rice wine and Weidefeng offered an authentic taste of local heritage. The bustling array of traditional New Year goods evoked cherished memories of a Jiaxing-style Spring Festival. Meanwhile, Nanhu Tiandi, Jiaxing’s most vibrant and trendy commercial district, has likewise embraced its festive transformation. Adorned with a series of celebratory art installations that seamlessly blend Jiangnan elegance with contemporary aesthetics, the area also hosts a lively New Year market running through the Lantern Festival. With photogenic scenes at every turn, the district embodies a stylish reinterpretation of traditional Chinese New Year spirit—where heritage meets modernity in the most captivating way. Encountering Ancient Jiangnan Towns: Immersing in the Slow Rhythms of Life Beyond the vibrant festive atmosphere, the influencers delved into Jiaxing’s rich tapestry of ancient cities and towns, exploring the city’s profound historical legacy across different eras and perspectives. At the Zicheng Archaeological Site Park, they wandered along the millennia-old city walls, listening to the silent stories embedded in every stone and experiencing the flow of Jiaxing’s history through centuries of change. Continuing to the Nanhu Tourist Resort, they ascended the iconic Misty Rain Pavilion against a backdrop of mist and drizzle, taking in sweeping views of Nanhu Lake and gazing upon the historic Red Boat—a timeless symbol enshrined in China’s revolutionary memory. At this convergence of red culture and Jiangnan scenery, they came to appreciate the city’s layered cultural identity. As night descended, an evening boat cruise offered a poetic conclusion to the day’s journey, weaving together the shimmering lights of Jiaxing’s waterfront. Gliding along the calm waters, the boat revealed a panorama of architectural silhouettes lining the shores—each telling its own story—unfolding like a living scroll of a “city that never sleeps,” both timeless and enchanting. “To Discover the Soul of Jiangnan’s Ancient Towns, Look to Jiaxing.” Xitang and Shendang unfold like two quietly turned pages from the chronicles of authentic Jiangnan life. Xitang Ancient Town, celebrated as a “living millennium-old town,” preserves remarkably intact clusters of Ming and Qing architecture, defined by its signature layout of “numerous bridges, winding lanes, and sheltered corridors.” Here, time seems suspended in a gentle, harmonious rhythm. Shendang Ancient Town, by contrast, offers a more tranquil and introspective experience. Largely untouched by excessive commercial development, it allowed the influencers to immerse themselves in the unspoiled, slow-paced essence of Jiangnan life. This journey by the Malaysian content creators stands as a vivid testament to Jiaxing’s cultural tourism vision—using the Spring Festival as a cultural bridge to share the refined aesthetics of Jiangnan with the world. Where time-honored New Year traditions converge with the legacy of ancient towns, and where revolutionary heritage intertwines with contemporary luminous artistry, Jiaxing reveals its uniquely inclusive and multifaceted character. It is crafting a fresh narrative for Spring Festival travel—one that blends festive richness with heartfelt experiences. Come, and discover a different kind of Jiangnan Chinese New Year.

Seattle, Washington – February 10, 2026 – (SeaPRwire) – Singer-songwriter Dr. Don has surpassed one million views on YouTube across three of his music videos in less than a year, marking a major digital milestone for the independent artist. The songs “Beautiful Vibes,” “Vodka Tonight,” and “Ruled by Time” have each crossed the seven-figure mark on the platform, with additional short-form video versions also reaching significant view counts. Dr. Don’s milestone highlights his rise as an independent artist, proving that multiple songs can attract large audiences without relying on traditional promotion. Strong performance across both full-length and short-form videos shows his ability to connect with listeners in different ways, marking a significant step in his career and illustrating how music can thrive organically in today’s digital landscape.  According to Dr. Don, “Ruled by Time” has become the strongest engagement anchor among the releases, continuing to generate repeat viewers, lyric-based comments, and ongoing discussion. He said the video has maintained active interaction well beyond its initial surge.  Dr. Don described “Ruled by Time” as a standout, noting its strong and sustained engagement. “It has become the strongest anchor among my releases. The video continues to show unusually high interaction with repeat viewers, lyric-based comments, and ongoing discussion,” he said. “Seeing people reference the lyrics and share their experiences shows the music is landing in a real way.”  The surge comes without a label machine, radio pipeline, or marketing firm behind it. Dr. Don is building this momentum on his own, releasing music independently and growing his audience one listener at a time.  Crossing the million-view mark across three separate songs in less than a year places him in rare company among truly self-directed artists. The numbers reflect not a campaign, but a connection, powered by repeat viewers, shared links, and sustained conversation around the music.  Each milestone strengthens his position as a solo creator proving that scale is still possible without gatekeepers. With multiple videos now hitting seven figures, Dr. Don is expanding his platform in real time, connecting with listeners globally while preparing his next projects. His work illustrates how focus, consistency, and authenticity can turn digital engagement into a tangible career milestone.  This is where music meets momentum. Visit Dr. Don’s official YouTube channel and follow him on social media for updates.  About Dr. Don  Dr. Don is a singer-songwriter and performer known for blending introspective lyrics, rich baritone vocals, and expressive movement to create immersive musical experiences. His work explores the complexities of human emotion, vulnerability, and personal growth. Beyond music, he draws on a background in law to inform his understanding of human behavior and storytelling, making each performance a unique reflection of artistry and self-expression.  Media Contact  Dr. Don  E: don@drdonmusic.com  W: https://drdonmusic.com/

Historic insurance partnership with Great American Insurance Group sets new standard for player protection KUALA LUMPUR, Malaysia – February 09, 2026 – (SeaPRwire) – playX today announced a milestone achievement in player protection, unveiling an industry-leading insurance policy secured through a strategic partnership with Great American Insurance Group (GAI), a trusted provider of gaming insurance solutions since 1995. The announcement was made during a special company event in Kuala Lumpur, highlighting playX’s continued commitment to strengthening financial safeguards for players across its platform. Official Video: https://www.youtube.com/watch?v=EpvceD-HJyU What This Means for Players The policy directly protects all playX players. If playX ever ceases operations, players can file claims directly with GAI to recover their funds — a first in online gaming history. Direct claim rights with Great American Insurance Group Platform insolvency protection for all player funds Backed by GAI’s 30-year track record in gaming insurance Guinness-verified player protection in online gaming “This isn’t just a title — it’s a guarantee that our players’ funds are protected by an independent, globally recognized insurer, not just our promises,” said Mark Carter, CEO of playX. About playX Premier online gaming platform serving Southeast Asia, combining cutting-edge technology with industry-leading security. About Great American Insurance Group Century-old insurance provider; Fidelity & Crime division has led gaming insurance since 1995. Official Channels Facebook: https://www.facebook.com/playX.my Instagram: https://www.instagram.com/playx.my/ Telegram: https://t.me/playXofficial YouTube: https://www.youtube.com/@playXOfficial8 Media contact Brand: playX Contact: Media team Email: marking@playxgaming.com Website: https://playx.my

New York, NY – February 01, 2026 – (SeaPRwire) – Recently, the world’s only Pokémon card graded PSA 10 – Pikachu Illustrator – once again became a focal point of global attention across the collectibles and cultural landscape. As a long-term contributor to TCG infrastructure and the broader collectibles ecosystem, The Collectors Grid(TCG.Zone) participated in and witnessed this historically significant moment. Recognized as one of the most iconic works in Pokémon card history, Pikachu Illustrator is distinguished not only by its extreme rarity, but also by its symbolic representation of Pokémon culture, artistic value, and generational memory. The Legendary Status of the World’s Only PSA 10 According to publicly available information, the world’s only PSA 10 “Pikachu Illustrator” card is currently owned by Logan Paul. The card was involved in a high-profile transaction in 2022, valued at nearly USD 5.3 million, marking a defining milestone in the history of Pokémon card collecting. The Industry Significance of Goldin Auctions Although Logan Paul’s acquisition of the card did not take place through Goldin, the Goldin auction platform has continued to play an important role in the card’s contemporary circulation and visibility. As one of the world’s most influential high-end collectibles auction platforms, Goldin’s auction framework and the attention it generates brought renewed global focus to this legendary card, further positioning Pokémon cards within the broader mainstream collectibles market. Netflix Documentary Captures a Cultural Moment Amid the phenomenon-level attention generated by this card on the Goldin platform, Netflix documented the full auction process and produced a dedicated documentary. Approached from a cultural and historical perspective, the documentary highlights the unique position of Pikachu Illustrator within the modern collectibles ecosystem, elevating it beyond price alone and framing it as a lasting cultural reference. Global Participation and TCG.Zone’s Involvement The discussions and auction activity surrounding Pikachu Illustrator attracted participation from top collectors, institutions, and professional teams from around the world. TCG.Zone was among the active participants in the bidding process. During the auction, TCG.Zone submitted a bid of USD 5,000,000. Although the bid was ultimately surpassed by a higher offer, TCG.Zone remained deeply engaged throughout the process and witnessed this pivotal moment firsthand. Continuing to Follow the Card’s Future Trajectory In post-auction interviews, TCG.Zone stated that this participation does not mark an endpoint. The team will continue to closely monitor the movement and future trajectory of the world’s only PSA 10 Pikachu Illustrator, and does not rule out participating again should the right opportunity arise. This event represents more than an auction. It stands as a collective reflection on rarity, cultural identity, and long-term value. The story of Pikachu Illustrator continues to unfold,and remains an enduring chapter in the global history of Pokémon card collecting. Social Links Twitter: https://x.com/tcgzoneofficial Instagram: https://www.instagram.com/tcgzoneofficial/ Telegram: https://t.me/tcgzoneofficial Media Contact Brand : The Collectors Grid (tcg.zone) Contact: Annie Email: hi@tcg.zone Website: https://www.tcg.zone

SHENZHEN, Jan 30, 2026 – (ACN Newswire via SeaPRwire.com) – China Medical System Holdings Limited (“CMS” or the “Group”) is pleased to announce that its subsidiary, Dermavon Holdings Limited (“Dermavon”, an innovative pharmaceutical company specialized in skin health which is applying for a separate listing on the Main Board of The Stock Exchange of Hong Kong Limited, please refer to the announcement published by the Group on 22 April 2025 for details) received approval from the National Medical Products Administration of China (NMPA) on 30 January 2026 for the New Drug Application (NDA) of ruxolitinib phosphate cream (the “Product”) for the treatment of non-segmental vitiligo with facial involvement in children aged 12 years and older and adult patients. It is the first and only targeted drug approved in China for vitiligo, addressing a significant unmet clinical need. Ruxolitinib phosphate cream is the first and only drug approved by the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for repigmentation in nonsegmental vitiligo[1,2]. Prior to receiving formal NDA approval, the Group benefited from the “Early and Pilot Implementation” policy granted to the Hainan Free Trade Port and Lecheng Pilot Zone (“Lecheng Pilot Zone”), the “Hong Kong and Macau Medicine and Equipment Connect” policy, and the clinically urgently needed imported drug policies of the Beijing and Tianjin Free Trade Zones, and had already initiated the pilot application of ruxolitinib phosphate cream. Currently, Boao Super Hospital has prescribed ruxolitinib phosphate cream to over 7,000 patients with non-segmental vitiligo, and more than twenty hospitals in Guangzhou, Shenzhen, Dongguan, Foshan, Zhongshan, Zhuhai, Jiangmen, Huizhou, Beijing and Tianjin have provided prescription services for the Product, demonstrating its clinical potential. The product has shown positive results in both overseas clinical studies and the real-world study in China: in two identical Phase III double-blind, randomized, placebo-controlled studies (TRuE-V1 and TRuE-V2) conducted overseas, the proportion of patients achieving the primary efficacy endpoint of at least 75% improvement in the Facial Vitiligo Area Score Index (F-VASI 75) after 24 weeks of treatment with ruxolitinib phosphate cream was 29.9% in both studies, significantly higher than the 7.5% and 12.9% in the placebo groups, respectively. Continued use up to 52 weeks showed sustained repigmentation[3]. In accordance with the relevant regulations of the Lecheng Pilot Zone’s real-world data application pilot project, ruxolitinib phosphate cream underwent real-world study in China, demonstrating positive efficacy consistent with the results of overseas pivotal clinical studies. All secondary efficacy endpoints in both domestic and overseas clinical studies showed a benefit trend consistent with the primary efficacy endpoint, and the treatment effect for vitiligo continued to improve with prolonged treatment. Furthermore, according to safety monitoring data from the Lecheng Pilot Zone, no new safety event was identified, no adverse event (AE) leading to discontinuation or withdrawal of treatment occurred, and no study drug-related serious adverse event (SAE) occurred. This approval in vitiligo brings new hope for treatment to over 10 million vitiligo patients in China, addressing urgent clinical needs. At the same time, it will add to Dermavon’s product portfolio in the field of skin treatment, potentially synergizing with Dermavon’s commercialized innovative drug ILUMETRI (tildrakizumab injection), commercialized exclusive drug Hirudoid (mucopolysaccharide polysulfate cream), and a series of innovative drugs under development and dermatological skin care products, in terms of expert network and market resources, thereby potentially enhancing Dermavon’s position in the field of skin health. Furthermore, the Phase III clinical trial in China of ruxolitinib phosphate cream for the treatment of mild to moderate atopic dermatitis (AD) has achieved positive results. Currently, the Group is actively advancing the NDA for ruxolitinib phosphate cream for the treatment of AD in China, which, if approved, will provide a new treatment option for a broader patient population with AD in China. About Vitiligo Vitiligo is a chronic autoimmune disease characterized by depigmentation of the skin, which results from the loss of pigment-producing cells known as melanocytes. It is estimated that there are approximately 10.3 million vitiligo patients in China and non-segmental vitiligo patients account for approximately 8.2 million[4]. Existing therapies, such as topical corticosteroids (TCS) and topical calcineurin inhibitors (TCIs), have clinical limitations, with adverse reactions or limited efficacy with long-term use. The NDA approval of ruxolitinib phosphate cream successfully fills the gap in targeted drug treatment for vitiligo and is of great landmark significance. More About Ruxolitinib Phosphate Cream Ruxolitinib phosphate cream (Opzelura®), a novel cream formulation of the selective JAK1/JAK2 inhibitor ruxolitinib developed by Incyte, is approved for the topical treatment of nonsegmental vitiligo in adult and patients aged 12 years and older, and for the short-term and non-continuous chronic treatment of mild to moderate AD in patients aged 2 years and older without immunodeficiency in the U.S. In Europe, ruxolitinib phosphate cream is approved for the treatment of non-segmental vitiligo with facial involvement in adults and adolescents from 12 years of age. The Group, through a subsidiary of Dermavon entered into a Collaboration and License Agreement with Incyte for ruxolitinib phosphate cream on 2 December 2022, obtaining an exclusive license to develop, register and commercialize the Product in Mainland China, Hong Kong Special Administrative Region, Macau Special Administrative Region, Taiwan Region and eleven Southeast Asian countries (the “Territory”) and a non-exclusive license to manufacture the Product in the Territory. The subsidiary of Dermavon has sublicensed the relevant rights for the Product outside Mainland China to the Group (excluding Dermavon and its subsidiary). Incyte has worldwide rights for the development and commercialization of ruxolitinib phosphate cream, marketed in the United States and Europe as Opzelura®. Opzelura® and the Opzelura® logo are registered trademarks of Incyte. About CMS CMS is a platform company linking pharmaceutical innovation and commercialization with strong product lifecycle management capability, dedicated to providing competitive products and services to meet unmet medical needs. CMS focuses on the global first-in-class (FIC) and best-in-class (BIC) innovative products, and efficiently promotes the clinical research, development and commercialization of innovative products, enabling the continuous transformation of scientific research into clinical practices to benefit patients. CMS deeply engages in several specialty therapeutic fields, and has developed proven commercialization capabilities, extensive networks and expert resources, resulting in leading academic and market positions for its major marketed products. CMS continues to promote the in-depth development in its advantageous specialty fields, strengthening the competitiveness of the cardio-cerebrovascular/ gastroenterology/ ophthalmology/ skin health businesses, bringing economies of scale in specialty fields. Among them, the skin health business (Dermavon) has become a leading enterprise in its field, and is proposed to be listed independently on the SEHK. Meanwhile, CMS continuously promotes the operation and development of its integrated R&D, manufacturing and commercialization chain in Southeast Asia and the Middle East, capturing growth opportunities in emerging markets to support the high-quality and sustainable development  of the Group. Reference: 1. The U.S. FDA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-us-fda-approval-opzeluratm-ruxolitinib-cream 2. The EMA approval information can be found on the Incyte official website, as follows: https://investor.incyte.com/news-releases/news-release-details/incyte-announces-european-commission-approval-opzelurar 3. The clinical studies information can be found on the Opzelura® official website, as follows: https://www.opzelura.com/opzelura-prescribing-information 4. China Insights Consultancy’s industrial report CMS Disclaimer and Forward-Looking Statements This press release is not intended to promote any products to you and is not for advertising purposes. This press release does not recommend any drugs, medical devices and/or indications. If you want to know more about the diagnosis and treatment of specific diseases, please follow the opinions or guidance of your doctor or other medical and health professionals. Any treatment-related decisions made by healthcare professionals should be based on the patient’s specific circumstances and in accordance with the drug package insert. This press release which has been prepared by CMS does not constitute any offer or invitation to purchase or subscribe for any securities, and shall not form the basis for or be relied on in connection with any contract or binding commitment whatsoever. This press release has been prepared by CMS based on information and data which it considers reliable, but CMS makes no representation or warranty, express or implied, whatsoever, and no reliance shall be placed on, the truth, accuracy, completeness, fairness and reasonableness of the contents of this press release. Certain matters discussed in this press release may contain statements regarding the Group’s market opportunity and business prospects that are individually and collectively forward-looking statements. Such forward-looking statements are not guarantees of future performance and are subject to known and unknown risks, uncertainties and assumptions that are difficult to predict. Any forward-looking statements and projections made by third parties included in this press release are not adopted by the Group and the Company is not responsible for such third-party statements and projections. Media ContactBrand: China Medical System Holdings Ltd.Contact: CMS Investor RelationsEmail: ir@cms.net.cnWebsite: https://web.cms.net.cn/en/home/

Moscow, Russia – January 31, 2026 – (SeaPRwire) – Expert Dialogues were held for the first time within the Open Dialogue framework at the Russia National Centre in Moscow on 30 January. The forum focused on five major megatrends shaping global economic, technological, and social development, bringing together international experts to explore how these forces will influence societies and industries in the decades ahead. Organized by the Russia National Centre in partnership with the Centre for Cross-Industry Expertise “The Third Rome” and supported by the Presidential Executive Office, the forum brought together experts from around the world to discuss economic, technological, and social transformations. Maksim Oreshkin, Deputy Head of the Russian Executive Administration for Global Trends, presented five key megatrends that, he said, are already shaping global development and will continue to influence the world in the coming decades. “By 2026, Open Dialogue has become an international platform uniting experts from across the world to discuss the future of the planet, the global economy, and society,” Oreshkin said. “Understanding these processes is essential for preparing for change and leveraging it in the interests of nations and, above all, people. Today, I will focus on five key megatrends — while not treating artificial intelligence as a separate trend, because it has already become an integral part of our lives.” 1. A New Global Economic Paradigm: Globalisation 2.0 A shift from traditional globalisation to a more decentralised system was described. BRICS+ countries now play a growing role in the global economy, technological development, and demographic trends, while the Global South is increasingly engaging in direct trade and national-currency settlements. “Globalisation hasn’t ended; it has changed,” Oreshkin said. “Sovereignty — at state, social, and economic levels — is now the key to competitiveness. Only countries that preserve all three levels can lead in a multipolar world.” China, the USA, India, and Russia are identified as major global powers, while highlighting emerging growth centres such as Indonesia and “connector countries” like the United Arab Emirates. Digital platforms and decentralised networks are also becoming independent participants in the world economy. 2. Platformisation and Institutional Automation The second megatrend highlights the rise of platforms and automation across all sectors. Platforms and algorithms are increasingly shaping decision-making in healthcare, education, finance, trade, and beyond. “Platform solutions enhance efficiency and reduce transaction costs through self-adjusting algorithms,” Oreshkin said. “Countries without technological sovereignty risk becoming dependent on external platforms, which can have strategic consequences during conflicts.” 3. Transformation of the Global Financial System It was noted that traditional financial models face mounting challenges, including rising public debt, widening inequality, and geopolitical fragmentation. Technologies such as blockchain, artificial intelligence, and digital platforms are creating alternative financial mechanisms, including decentralised finance. “The traditional model of cross-border payments is under pressure. Decentralised systems and digital technologies are reshaping the financial system,” he said. 4. Demographic Shifts and Challenges The fourth megatrend concerns global population dynamics. Global fertility rates have fallen sharply, with some countries facing critical declines. By the end of the 21st century, the working-age population may shrink significantly, while the proportion of elderly people rises, placing pressure on pension systems and social services. “Even in Africa, the ratio of elderly to working-age population will rise to 30%, and globally to 56%,” Oreshkin explained. “Education demand will decrease, but healthcare and social service needs will grow. These interconnected trends will amplify each other.” 5. Human Capital Development in the Technological Era The final megatrend focuses on human capital in a rapidly changing technological environment. Autonomous systems, digital platforms, and artificial intelligence are transforming education, work, and healthcare, while biotechnologies expand human capabilities. “AI is both a challenge and an opportunity,” Oreshkin said. “It allows personalized learning paths and supports teachers. Professions are changing: mid-level specialists will be in demand, and companies must retrain employees from junior positions. The social sphere will also evolve, ensuring active longevity in the new demographic era.” Global Perspective Throughout the presentation, Oreshkin illustrated each trend with real-life examples from different continents: a manager from Asia, a farmer from Africa, and a homemaker from Eastern Europe. He highlighted that innovations in Africa could improve education and healthcare, Eastern Europe may see rising living standards and more efficient social systems, and Asia will require reskilling to meet changing labor demands. “The world has entered a period of significant change in finance, demography, and other spheres. States, companies, and individuals must be prepared. Those who understand and adapt will shape the future,” Oreshkin concluded. Open Dialogue on Air This year, Open Dialogue introduced a podcast format — Open Dialogue on Air — featuring global experts discussing key trends in international development. Participants include award-winning Chinese sci-fi writer Chen Qiufan, Dr. Selina Neri of the Future Readiness Academy, Dr. Rais Hussin of EMIR Research (Malaysia), Prof. Wang Feng of UC Irvine, and global strategist Dr. Parag Khanna. First held in April 2025 at the Russia National Centre, the Open Dialogue brought together over 3,000 experts from dozens of countries. By presidential decree, it will now be held annually. Social Links Telegram: https://t.me/gowithrussia VK: https://vk.com/gowithrussia OK: https://ok.ru/gowithrussia DZen: https://dzen.ru/gowithrussia Contact for the media Brand: Russia National Centre Contact: Media team Email: Pressa@russia.ru Website: https://russia.ru Essay Submission: https://dialog.russia.ru/en/

Singapore - January 30, 2026 - (SeaPRwire) - 抵押貸款債務代幣化先驅平台CoinLander正式宣布其累計市場規模突破140萬美元。此里程碑距平台於2025年10月20日公開上線僅11週。自去年11月13日達成60萬美元後迅速增長至當前水平，標誌著投資者情緒的決定性轉變。在數位資產市場持續波動之際，資金正積極轉向有擔保、具收益性的工具。透過讓投資者資助抵押貸款而非投機房產權益，CoinLander驗證了加密貨幣市場對穩定債務收益型產品的強勁需求。 實體資產代幣化領域，品質為核心 CoinLander的增長軌跡反映了數位資產領域更廣泛的成熟化趨勢。投資者正逐漸遠離投機性代幣，轉向具有實體資產支撐的實體資產代幣化項目。數據支持這股遷移潮：RWA領域目前估值達192.5億美元，僅過去30天即上漲3.33%。此前在2025年，該領域因機構與零售參與者尋求避險而非投機回報，已大幅增長237.14%。 採用指標亦呈現相似趨勢。2025年間，持有RWA資產的獨立地址數量增長七倍，從約8.4萬個躍升至近58.8萬個。CoinLander正搶占此擴張市場中的特定區塊：即渴望傳統金融結構可靠性、卻不欲承受傳統銀行繁瑣流程的投資者。 「成為銀行」模式受市場青睞 CoinLander近期資金流入的關鍵驅動力，在於其獨特的運營模式。多數RWA平台將房產權益代幣化—使用戶成為依賴房產升值的分權房東—而CoinLander則將抵押貸款本身代幣化。此結構讓投資者得以「成為銀行」。用戶無需等待多年房產出售以實現利潤，而是從借款人的每月利息支付中賺取穩定收益。 這種以債權為核心的方法，解決了房地產眾籌常見的流動性問題，並切入了一個深度巨大的市場。2025年11月，美國抵押貸款債務規模達13.5兆美元，佔該國GDP的44%。透過將此資產類別引入鏈上，CoinLander提供了一種成長天花板極高、且與比特幣或以太坊價格波動無關的產品。 100%完投率與最高12%年化收益率 信任建立在績效之上，而CoinLander自去年10月上線以來保持零失誤紀錄。平台已成功推出23個抵押貸款項目，完投率達100%，為參與者提供持續回報。當前資金池提供最高12%的年化收益率，此數字對股市投資者與DeFi原住民皆具吸引力。 CoinLander創始人兼執行長RΞN表示：「在如此短的時間內躍升至140萬美元，證明了市場渴望合理的收益型產品。我們正見證一場融合：股市投資者追求比債券更高的收益，而加密貨幣投資者希望在不離開生態系的前提下避開波動性。CoinLander透過將債務而非建築物代幣化，解決了傳統房地產的流動性困境。我們提供抵押貸款的穩定性，兼備區塊鏈的速度。」 欲了解項目詳情或當前抵押貸款資金池更多資訊，請訪問CoinLander官網，並關注其在X、Telegram與LinkedIn的官方動態。 關於CoinLander CoinLander 是連結傳統金融與數位資產經濟的先驅實體資產代幣化平台。其將高品質的現實世界抵押貸款債務代幣化，讓用戶能賺取由實體房產擔保的可預測月收益。平台於2025年10月20日正式推出，將非流動性的房地產債務轉化為可及的數位投資品，為波動的傳統加密市場提供穩定替代選擇。上線不到四週，CoinLander的總鎖倉額即突破60萬美元，並於2026年1月5日前攀升至逾140萬美元，顯示市場對加密領域中穩定抵押貸款收益產品的強烈需求。

In Collaboration with MAGO Moon Museum, Opening the “$VIVI RWA MARKET” Singapore – January 29, 2026 – (SeaPRwire) – LEGENDARY HUMANITY, a Singapore-based company listed on Gate.io, has announced the launch of the “$VIVI RWA MARKET,” a new Real World Asset (RWA) marketplace enabling the purchase of exhibited works by contemporary artist Mago Nagasaka. Developed in collaboration with the MAGO Moon Museum, this launch marks a significant milestone in LEGENDARY HUMANITY’s ongoing efforts to bridge cultural value and digital infrastructure through real-world assetization. Digitalizing Humanity’s Masterpieces Through AI 3D Scanning Technology – A New Purchasing Experience Led by LEGENDARY HUMANITY LEGENDARY HUMANITY PTE. LTD. (Headquarters: Singapore; CEO: Takamasa Suzuki) has officially opened the “$VIVI RWA MARKET,” an RWA marketplace where visitors can directly purchase artworks exhibited in the online museum “MAGO Moon Museum,” created by contemporary artist Shingo Nagasaka. This initiative forms part of the “VIVI PROJECT,” which aims to digitize humanity’s masterpieces into digital assets through high-precision, non-contact AI-integrated 3D scanning technology. Through this platform, visitors are able to acquire artworks they have viewed within MAGO Moon Museum as RWAs, enabling a deeper engagement with the artist’s worldview and creative philosophy. Overview Name: $VIVI RWA MARKET Opening Date: Thursday, January 29, 2026 URL: https://mondo.lhvivi.io/ About “$VIVI RWA MARKET” The “$VIVI RWA MARKET” is an RWA marketplace dedicated to the acquisition of artworks and is embedded within the online museum MAGO Moon Museum. Seamless Pathway from Viewing to Purchase Users can seamlessly transition from an artwork’s exhibition page to its corresponding RWA product page, creating a unified experience from online viewing to ownership. Integration of Physical and Digital Asset Design Each artwork includes the following structured information: Physical artwork details (size, materials, condition, provenance) High-resolution digital data generated through AI 3D scanning Artist profile and project background information along with other curated metadata. This structure allows users to acquire artworks with a proper understanding of their cultural and artistic value. Ecosystem Holding Functionality Acquired works will gradually gain viewing and management functionality within the VIVI ecosystem. While future integration with VIVI COiN is under consideration, the current initiative is focused solely on enhancing the preservation, appreciation, and understanding of the artworks. About LEGENDARY HUMANITY and the VIVI PROJECT LEGENDARY HUMANITY promotes the “VIVI PROJECT,” which digitizes legendary masterpieces created by humanity into digital assets using high-precision, non-contact, AI-integrated 3D scanning technology. The project operates under the vision of “Bringing the beauty of humanity to AI and the future.” Targeted assets include: Legendary fashion collections Historical architecture and cultural masterpieces Famous trading cards Artworks, including those exhibited at MAGO Moon Museum and other assets that can be described as humanity’s masterpieces. The VIVI PROJECT aims to: Digitize assets as digital cultural heritage Tokenize them as RWAs for global circulation Exhibit them in both online and physical museums thereby building new infrastructure that harmonizes cultural and economic value. NEXT SOCIETY (Gacha Location): https://nextsociety.lhvivi.io RWA Market Roadmap The launch of the “$VIVI RWA MARKET” represents the first phase of RWA market functionality within the VIVI PROJECT. Planned future developments include: VIVI FASHION (RWA for the fashion domain) VIVI TRADING CARD (RWA for the trading card domain) VIVI ART WORK (RWA for art collections) with future integration under consideration. About MAGO Moon Museum MAGO Moon Museum is an online museum created by contemporary artist Shingo Nagasaka, whose works explore themes related to electronic waste issues in Agbogbloshie, Ghana. The museum provides an online space to view Nagasaka’s representative works, including pieces created from discarded electronic components found in Ghanaian slums, as well as series examining the concept of “Sustainable Capitalism.” With the implementation of the “$VIVI RWA MARKET,” viewers can deepen their understanding of the artworks while acquiring pieces aligned with the artist’s philosophy in an appropriate and structured manner. Future Developments Building on this initiative, LEGENDARY HUMANITY plans to: Expand collaborations with masterpieces across different regions and genres Strengthen international networks with artists, collectors, and researchers Advance technological development for the preservation of cultural assets for future generations and continue developing as a platform that passes humanity’s masterpieces into the future through real-world assets. Media Contact Company Name: LEGENDARY HUMANITY PTE. LTD. Address: 105 Cecil St, The Octagon 24F-2, Singapore 06953 Representative: Takamasa Suzuki, LEGENDARY HUMANITY / VIVI PROJECT Public Relations Desk Email: info@lhvivi.com Related URL: $VIVI RWA MARKET https://mondo.lhvivi.io

Commences building an RWA (Real-World Asset) token economy Maximizing Value Through Digitalization Using Cutting-Edge 3D Scanning Technology “SCAI” and RWA Indexing New York, NY – January 20, 2026 – (SeaPRwire) – VIVI PROJECT (formerly LEGENDARY HUMANITY) announces a major update and rebranding. The project utilizes the latest 3D scanning technology “SCAI” to digitally archive humanity’s cultural heritage, providing training data for AI and building a new token economy based on RWA (Real World Assets). Background and Project Evolution Previously, “LEGENDARY HUMANITY” aimed to digitize humanity’s greatest masterpieces using cutting-edge technology, teaching AI about “humanity’s magnificence” to preserve its value for future generations. With this update, the project is renamed “VIVI PROJECT.” Moving beyond mere archiving, it will challenge the creation of new value in the Web3 era as an “RWA token project” building a unique economic ecosystem backed by real-world assets (RWA). The Four Pillars of the “RWA Ecosystem” Provided by VIVI PROJECT Digitization via High-Precision 3D Scanning Technology “SCAI:DIGITAL LUMINOUS Technology” Digitizing humanity’s treasures and providing them as AI training data. Merging human wisdom with technological evolution. Adding RWA Value to VIVI COiN: Centered around the project token “VIVI COiN,” we plan to link RWA held by collectors partnered with “VIVI PROJECT” to enhance the project’s value.By using “LEGENDARY masterpieces” whose value appreciates over time as the foundation for “VIVI COiN,” we build a stable value base. Hybrid Digital & Physical Museum Collected RWAs will be displayed in both digital museums and physical exhibition facilities. Trading via the marketplace will also be enabled, enhancing liquidity as an asset. VIVI DAO’s “Buy-Back & Burn” Model The governing body, “VIVI DAO,” will use exhibition and sales revenue to implement “Buy-Back” and “Burn” of VIVI COiN. This will increase the token’s scarcity and promote long-term value appreciation. Future Outlook: Global Collection Partnerships The VIVI PROJECT is advancing the networking of collections held by global asset owners. As a first step, we have initiated the following partnerships and negotiations: LA MUSEUM: Holds one of the world’s largest legendary fashion collections, including Yves Saint Laurent, Comme des Garçons, Worlds End, Alexander McQueen, John Galliano, and Madison Martin Margiela. Major Trading Card Company: Negotiations have commenced with the world’s largest trading asset company. This will integrate Real-World Assets (RWAs) from diverse genres like fashion, art, and hobbies into the project, rapidly expanding the ecosystem. VIVI PROJECT Overview VIVI PROJECT is a next-generation platform that preserves and utilizes humanity’s greatest masterpieces in both digital and physical realms through the fusion of culture and technology. By indexing RWA, it defines new asset value in the Web3 era. Official Website: https://lhvivi.com Contact for Inquiries Contact: VIVI PROJECT PR Department Email: press@lhvivi.com

Riyadh, Saudi Arabia  - 2026年1月18日 - (SeaPRwire) - 昨晚（週六），第六屆歡樂獎2026在利雅得隆重舉行。本次活動隸屬於“利雅得季”，由沙烏地阿拉伯總娛樂管理局主辦，並與中東廣播中心建立戰略合作夥伴關係。儀式在總娛樂管理局主席圖爾基·阿勒謝赫閣下的出席下舉行，彙聚了來自電影、電視劇、音樂、體育及數字內容領域的阿拉伯及國際頂級人物，現場媒體關注度極高，公眾互動熱烈。 頒獎典禮通過多個電視頻道進行現場直播，並在數字平臺同步播出。觀眾從明星們踏上薰衣草色地毯的瞬間開始，全程關注了包括獎項頒發、榮譽表彰以及多段現場音樂和表演在內的完整娛樂盛典。 當晚在充滿節慶氛圍的環境中拉開序幕，藝術家和名人陸續抵達，現場媒體對明星首次亮相給予了高度關注。隨後，圖爾基·阿勒謝赫閣下抵達現場，成為官方節目開始前的重要時刻。沙特國歌奏響後，典禮進入震撼的開場娛樂表演。 世界知名歌手凱蒂·佩裏獻上獨具特色的開場演出，表演融合了交響樂元素、舞者與視覺特效，通過動態燈光與強烈的舞臺表現力，呈現出高度製作化的藝術畫面，充分體現了本屆活動的規模與精密籌備。 隨後，國際表演團體皮洛博魯斯帶來影子舞表演，以創新且節奏輕快的視覺形式重新吸引觀眾注意力。接著，頒獎環節依照流程正式展開，現場嘉賓與媒體在結果揭曉前充滿期待。 拉贊·賈邁勒與梅娜·沙拉比共同頒發“最受歡迎電視劇男演員獎”。提名者包括《阿什拉街》的阿蔔杜勒拉赫曼·本·納菲亞、《碼頭》的阿蔔杜勒莫赫森·納默、《呼吸》的穆塔塞姆·納哈爾，以及《非常擁擠的公寓》的希沙姆·馬吉德。最終，阿蔔杜勒莫赫森·納默榮獲該獎項。 隨後，圖芭·比尤克烏斯滕與哈利特·埃爾根奇頒發“最受歡迎黎凡特地區電視劇獎”。入圍作品包括《阿塞爾》《血之中》《七層之下》和《薩爾瑪》，最終《薩爾瑪》獲獎，劇組成員登臺領獎。 在終身成就獎特別環節中，圖爾基·阿勒謝赫閣下親自表彰埃及著名畫家、前文化部長法魯克·胡斯尼，以表彰其長期以來的藝術成就與文化貢獻。閣下表示能親自授予這一榮譽深感榮幸，胡斯尼則對沙特王國、其領導層及閣下本人表達了由衷感謝。 “最受歡迎新晉電視劇明星獎”由麥·奧馬爾與穆罕默德·薩米頒發。提名者包括《我的母親》的塔拉夫·奧拜迪、《薩爾瑪》的羅西爾·易蔔拉欣、《無陽光》的阿裏·拜亞利，以及《阿什拉街》的拉瑪·阿蔔杜勒瓦哈蔔。最終，塔拉夫·奧拜迪獲得該獎項。 隨後，音樂表演再次成為焦點，安甘與波蘭吉他演奏家馬爾欽同台獻藝，現場互動熱烈。典禮繼續進行，由穆罕默德·亨迪迪頒發“最受歡迎海灣地區電視劇獎”，《碼頭》《我的母親》《阿什拉街》《劍99》入圍，最終《阿什拉街》獲獎。 “最受歡迎電視劇女演員獎”由巴裏什·阿爾杜奇與漢德·埃爾切爾頒發。提名者包括《我的母親》的阿拉努德·蘇歐德、《阿什拉街》的伊勒哈姆·阿裏、《無陽光》的阿米娜·哈利勒，以及《七層之下》的卡麗絲·巴沙爾。最終，卡麗絲·巴沙爾獲獎。 “最受歡迎埃及電視劇獎”由李秉憲與李政宰共同頒發，入圍作品包括《伊什·伊什》《非常擁擠的公寓》《艾莎的房間》《無陽光》，最終《非常擁擠的公寓》榮獲該獎。 Media contact Brand: Legends PR Contact: Media Center Email: PR@legends.sa Website: https://legends.sa

在人工智慧（AI）與金融科技全面融合的今日，數位投資正掀起全球新浪潮。林學明教授攜手Thoma Bravo資本，以前瞻視野與專業經驗，推動AI與雲端應用於實務層面的整合，並正式對外說明亞太地區AI數位投資的合夥人參與機制，為市場建立更具系統性與紀律性的合作模式。 專業與科技的結合 林學明教授長期深耕金融市場，專注於量化策略與風險管理，累積豐富的實務經驗。本次與 Thoma Bravo資本 的合作，結合市場實務經驗與國際成熟的企業級軟體與 AI 架構，形成一套更具結構性與可複製性的運作體系。 Thoma Bravo資本為國際間專注於企業級軟體與科技領域投資的知名機構，長期關注具備穩定現金流與高黏著度的軟體公司，並以參與營運、優化效率著稱。其在AI、雲端與資料分析方面的實務經驗，已廣泛應用於歐美市場的企業與決策環境。 AI雲端應用：從經驗導向走向系統協作 在高度變動的市場環境中，單一經驗判斷已難以因應複雜情境。透過AI與雲端系統的輔助，可即時整合市場資訊、優化決策流程，降低人為與情緒因素干擾，使整體運作更趨穩定與理性。 合夥人機制：從前期觀察走向制度化參與 本次同步對外說明，「晚鳥班」屬於前期觀察與磨合的安排，並非傳統教學課程。透過多階段的實際互動，團隊觀察參與者的出席穩定度、配合度與執行一致性，並於相關流程完成後，開放部分符合條件者，以 編外合夥人 的形式，參與後續AI系統的制度化運作。 合夥人並非投資或決策角色，而是以既定流程參與系統協作，由系統自動完成相關數據的採集與紀錄，支撐AI模型在亞太市場的在地化應用。整體設計強調制度化、可複製與長期穩定，不涉及主觀判斷或操盤行為。 合作定位清楚，角色分工明確 在此架構下，專業分析與系統設計由團隊負責，合夥人則依流程配合執行。相關流程與分工清楚明確，課程結業證書的核心價值，亦體現出後續專案參與 與合作機會的優先權，形成有序且可延續的合作模式。 展望未來 隨著AI與數位科技持續演進，林學明教授與Thoma Bravo資本，將持續深化合夥人參與機制與系統化協作模式，探索更符合亞太市場特性的制度化運作方式，推動區域投資環境朝向更成熟、理性與穩定的方向發展。

在全球金融環境不斷變化、投資者對穩定性與透明度需求持續提升的背景下，0bo投資有限公司（0bo Capital Ltd.）致力於通過專業化與智能化手段，降低投資參與門檻，讓更多人能夠以更輕鬆的方式接觸專業級資產管理服務。 0bo 的名稱源自“Zero + Boost”。“Zero”代表公司對投資者的核心承諾 零門檻、零難度、零負擔與零焦慮；“Boost”則象徵以金融科技和專業策略，為資產的長期穩健增長提供理性支持。0bo 所倡導的，是“從零開始，安全增值”的投資理念，而非追求短期高波動的激進模式。 0bo投資有限公司總部位於美國科羅拉多州格林伍德村，是一家面向全球市場的資本管理機構。目前公司資產管理規模達518億美元，在全球設有27個辦事處，員工近2500名，團隊由經驗豐富的投資專家、研究人員及專業運營人員組成，服務對象涵蓋政府機構、企業客戶、機構投資者及個人投資者。 在服務模式上，0bo 強調定製化與長期視角。公司通過專業投資顧問體系，結合投資者的風險偏好與目標，提供個性化的資產配置方案，力求在複雜多變的市場環境中，幫助客戶實現更穩定、可持續的財富增長。 跨境運營方面，0bo 依託其全球戰略佈局與對金融體系的深入理解，在基金收付款與結算環節中合理運用 USDT 等穩定型數字資產工具，以提升跨區域結算效率與資金流動性。USDT 被定位為結算與技術工具，其價格穩定性與全球適用性有助於支持國際投資活動的順暢進行。 投資策略層面，0bo 高度重視風險管理與結構設計。公司通過數據分析與多層次投資模型，識別優質投資機會，並運用對沖策略降低整體波動。其中，A 類份額基金與 B 類份額基金通過不同期限與工具配置形成互補，在市場利率變化等情況下實現風險對沖，從而提升母基金的整體穩健性。 0bo 始終認為，投資無法完全消除風險，但可以通過專業設計與理性管理降低不確定性。因此，公司在對外溝通中堅持透明、剋制與長期視角，強調投資決策需建立在充分理解和審慎判斷之上。 展望未來，0bo投資有限公司將持續以金融科技與專業研究為基礎，完善全球資產配置能力，為更多投資者提供清晰、穩健、可持續的資本管理解決方案。

Mexico City, Mexico – January 10, 2026 – (SeaPRwire) – Excent Capital has announced the launch of a new incentive program for its global partner network, offering exclusive experiences connected to the 2026 World Cu as part of its ongoing commitment to long-term collaboration and partner engagement. The initiative is designed to recognise partner performance and strengthen relationships through experiences that go beyond traditional rewards. Depending on performance tiers, partners may qualify for packages that include match tickets, travel arrangements, accommodation, and curated experiences in the United States during the tournament. Rather than focusing solely on volume, the program is structured to encourage sustainable growth, strategic alignment, and continued collaboration between Excent Capital and its partners. The incentive tiers are linked to clearly defined performance benchmarks, ensuring transparency and consistency across regions. “We work very closely with our partners on a daily basis, and this initiative is a way to give something back that goes beyond numbers,” said Andrés Espinosa, Senior Business Development Manager at Excent Capital. The World Cup 2026 incentive program is open to eligible partners worldwide and will run until May 15. Participation details, performance criteria, and tier qualifications are communicated directly to partners through Excent Capital’s regional business development teams. About Excent Capital Excent Capital is a global trading broker offering access to a wide range of financial markets. Operating on proprietary, in-house developed technology, the company focuses on transparency, execution quality, and partner-driven growth, supporting partners through education, consistent market insight, and collaborative initiatives. Contact Information Organization: Excent Capital Contact Person: Ryccielli Ongaratto, Marketing Manager Email: support@excent.capital Website: https://excent.capital/